Cambridge Consultants and Neuro Engineering Technologies Research Institute (NETRI) announce a breakthrough in precision imaging of brain activity. Working with NETRI’s brain-on-a-chip technology and lensless imaging approach that detects the activity of neurons in brain tissue, Cambridge Consultants was able to accelerate the processing of individual images by over three orders of magnitude, moving from about 20 minutes to process an image to just hundreds of milliseconds. This step-change in speed opens up radical new possibilities, including real-time processing of neural activity and mimicking of neural activity on engineered platforms, supporting the development of novel treatments for conditions such as Parkinson’s and Alzheimer’s diseases.
We design disruptive technology to revolutionize diagnosis and treatment
Organ-on-a-chip is an emerging and highly promising area of biomedical research. The technology involves the ex-vivo (outside of the body) simulation of organ function on a chip. The ultimate promise of such technologies is to greatly reduce the time and cost of testing new therapies for safety and efficacy. Brain-on-a-chip technologies seek to apply this approach to the neural circuitry of the brain, the most complex organ in the human body.
French startup NETRI creates disruptive technologies for brain-on-a-chip applications in neuroscience. Its focus is on ex-vivo replication of human neural circuits in order to understand how neurological disorders, treatments and chemicals affect the brain. NETRI uses a combination of brain-on-a-chip technology and lensless microscopy to record the activity of millions of connected neurons, mimicking the neural circuits implicated in neurological disorders.
However, by detecting something as complex as neural activity, the approach generates an enormous amount of data, requiring many hours of computation effort in order to fully reconstruct the spatio-temporal map of neuron communication. The imaging system runs at approximately 1,000 frames per second, and the baseline algorithm took an average of 1,090 seconds – 18 minutes – to process a single image on a powerful desktop PC. Without improvement, a single second of recording can take 12 days to process.
Recognizing its world-class expertise in medical imaging and high-performance computation, NETRI approached Cambridge Consultants to address this bottleneck, challenging the company to develop a radical algorithm acceleration. A scientific imaging team was set to work within the company’s Data Lab, an on-site facility with state-of-the-art compute infrastructure, allowing rapid exploration of data and compute-heavy approaches, such as high-definition imaging and deep learning.
Cambridge Consultants selected the NVIDIA DGX POD architecture for their AI infrastructure, deploying the NetApp ONTAP AI solution that combines NVIDIA DGX-1™ with NetApp ONTAP storage and network fabric. Through a series of optimizations, the team was able to show that the NVIDIA DGX-1 system delivers the AI supercomputing power required to process a frame in an average of 0.3 seconds, around 3,000 times quicker than the original approach. This acceleration was achieved through a series of optimizations including the design and application of mathematical and algorithmic improvements, leveraging NumPY GPU-accelerated with RAPIDS (CuPy), and exploiting the sheer power of the DGX-1 system. The combined result enables NETRI to completely reimagine their approach and to set their sights on the most radical possibilities, including developing a fully scalable and real-time medical service for hospitals and pharmaceutical industries to perform both in-vitro diagnostics and personalized treatment for every patient suffering from a neurological condition.
Sally Epstein, Head of Strategic Technology at Cambridge Consultants, commented: “Lensless imaging replaces traditional optics with computation, creating a new set of optimization challenges that our team was excited to address. We’re proud to be at the leading-edge of developments in brain-on-a-chip technology and neural imaging, at the point where radical improvements can be unlocked by those with the right combination of vision, experience and compute power.”
Thibault Honegger, Chief Scientific Officer, President & Co-founder of NETRI, commented: “By combining the expertise of Cambridge Consultants with NVIDIA-based computational power, the real-time processing of neural communications becomes possible. This can mark a paradigm shift in assessing the functional aspects of in-vitro neural networks. With this level of resolution, we will be able to accurately measure the “wellness” of the network, in relation to neurological conditions and potential recovery.”
About Cambridge Consultants
Cambridge Consultants develops breakthrough products, services and intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 60 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 800 team members, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA), Tokyo (Japan) and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, energy and wireless communications.
Visit us: www.cambridgeconsultants.com
About Capgemini Invent
As the digital innovation, design and transformation brand of the Capgemini Group, Capgemini Invent enables CxOs to envision and shape the future of their businesses. Located in nearly 40 studios and more than 60 offices around the world, it comprises a 10,000+ strong team of strategists, data scientists, product and experience designers, brand experts and technologists who develop new digital services, products, experiences and business models for sustainable growth.
Capgemini Invent is an integral part of Capgemini, a global leader in partnering with companies to transform and manage their business by harnessing the power of technology. The Group is guided everyday by its purpose of unleashing human energy through technology for an inclusive and sustainable future. It is a responsible and diverse organization of over 325,000 team members in more than 50 countries. With its strong 55-year heritage and deep industry expertise, Capgemini is trusted by its clients to address the entire breadth of their business needs, from strategy and design to operations, fueled by the fast evolving and innovative world of cloud, data, AI, connectivity, software, digital engineering and platforms. The Group reported in 2021 global revenues of €18 billion.
Get The Future You Want
Visit us at www.capgemini.com/invent
NETRI has unique expertise and technologies in microfluidics engineering. NETRI designs, fabricates and exploits 3D microfluidics chips dedicated to neuroscience, aiming at understanding the structural and functional mechanistic of neural circuits, neurological disorders or potential novel treatments. Using a multi-compartments approach, we can reproduce in vitro neural networks of every complexity up to connectome-on-chip. Using rodent or iPSCs cells, physiologically relevant conditions can be replicated using NETRI’s NeurofluidicTM chips: Multi-nodes neural/non neural interfaces, neural circuits of every complexity, controlled structural connectivity, functional network recording, co-cultures in all nodes with fluid isolation, controlled microenvironment with disease-related injury, high-throughput microscopy compliance and small amount of reagents.
NETRI currently collaborates with pharmaceutical companies, CROs, academic researchers and medical doctors to accelerate the understanding of neural troubles mechanisms and the discoveries of new treatments. For further information: www.netri.fr/
Chief Scientific Officer, President & co-founder
+33 48762 8118
- artificial intelligence
- medical technology